BridgeBio Pharma-backed infigratinib scored a statistically significant win in a Phase 3 NEJM trial for children with achondroplasia, improving multiple growth endpoints versus placebo over 52 weeks. In the full analysis of 114 randomized participants, annualized height velocity increased by 1.74 cm per year (P<0.001) and height z score rose by 0.32 (P<0.001). Adverse events were common across both arms—71 of 74 participants in the infigratinib group and 37 of 39 in the placebo group reported events—but the study reported no serious adverse events attributable to the drug by investigators. Serious adverse events occurred in 4 of 74 on infigratinib versus 1 of 39 on placebo. Clinically, the package suggests a meaningful growth effect in a population with limited options, while the differing safety profile findings will likely shape how regulators and payers view risk management as development proceeds.